BOSTON--(BUSINESS WIRE)--TREM Rx, Inc., a biotechnology company with a proprietary technology platform for novel vaccines delivered to the skin, announced today the results of an in vivo preclinical study that shows, for the first time, that powerful cells of the immune system called TREMs (T Resident Effector Memory cells) prevalent in the skin can mediate a protective immune response that is far stronger than memory T cells that circulate in the bloodstream. The study was published in today’s online edition of Nature1 and was led by TREM Rx scientific founder, Dr. Thomas S. Kupper, the Thomas B. Fitzpatrick Professor of Dermatology at Harvard Medical School, and chair of Dermatology at Brigham and Women’s Hospital and the Dana Farber Cancer Institute.
